Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compartment-locked IL-12
- Development stage
- Preclinical
- Lead developer
- InCephalo
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
Compartment-locked IL-12 (also known as InC01 or InC-01) is a preclinical-stage, compartment-locked recombinant fusion protein consisting of interleukin-12 (IL-12) cytokine fused to an IgG4 Fc domain. Developed by InCephalo Therapeutics (a spin-off from the University of Zurich), it is engineered using the proprietary C-Lock platform to abrogate binding to the neonatal Fc receptor (FcRn) through specific amino-acid substitutions at the Fc:FcRn interface. In glioblastoma, FcRn is upregulated and typically exports Fc-fused biologics from the brain into the systemic circulation, leading to peripheral toxicity. By silencing FcRn binding, compartment-locked IL-12 remains localized within the central nervous system (CNS) compartment after local administration (such as convection-enhanced delivery), enhancing local anti-tumor efficacy while minimizing systemic exposure and associated cytokine-related toxicities.
- Other names
- C-Locked IL-12C-Locked IL-12FcCL IL-12CL IL-12Fccompartment locked IL-12
02
Targets
IL12RB2 (Interleukin-12 receptor subunit beta-2)
Beyond the preview
Go deeper on compartment-locked IL-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compartment-locked IL-12.